{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:34:27Z","timestamp":1789014867021,"version":"build-2803163510"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,2,18]],"date-time":"2022-02-18T00:00:00Z","timestamp":1645142400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,18]],"date-time":"2022-02-18T00:00:00Z","timestamp":1645142400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>New therapies are needed for relapsed\/refractory (R\/R) B-cell non-Hodgkin lymphoma. This phase 1b, open-label trial evaluated two anti-CD20-based triplet combinations.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Patients with R\/R follicular lymphoma (FL; <jats:italic>n<\/jats:italic>\u2009=\u200913) were treated with obinutuzumab, atezolizumab, and polatuzumab vedotin (G-atezo-pola; 1.4\u00a0mg\/kg\/1.8\u00a0mg\/kg) and patients with R\/R diffuse large B-cell lymphoma (DLBCL; <jats:italic>n<\/jats:italic>\u2009=\u200923) received rituximab (R)-atezo-pola. The primary efficacy endpoint was complete response (CR) at end of induction (EOI) by PET-CT (investigator assessed; modified Lugano 2014 criteria). Safety endpoints were also assessed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>13 FL patients were treated and evaluable for safety; 2\/23 DLBCL patients did not receive treatment and were not included in the safety population. Median observation time was 23.3 and 5.7\u00a0months in the FL and DLBCL cohorts, respectively. At EOI, CR rates in FL patients treated with G-atezo-pola at pola doses of 1.4\u00a0mg\/kg (<jats:italic>N<\/jats:italic>\u2009=\u20093) and 1.8\u00a0mg\/kg (<jats:italic>N<\/jats:italic>\u2009=\u20097) were 33% and 14%, respectively. In DLBCL patients receiving R-atezo-pola, the CR rate at EOI was 13%. In the FL cohort, 62% of patients experienced a grade 3\u20135 adverse event (AE; including two deaths) and 31% developed a serious AE (SAE). In DLBCL patients, R-atezo-pola was associated with a lower incidence of grade 3\u20135 AEs (24%; one death) and SAEs (10%). In both cohorts, the most common grade 3\u20135 AEs were hematologic toxicities.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Based on these safety issues, considered as related specifically to G-atezo-pola, and limited efficacy, no further development of either combination is planned.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>NCT02729896; Date of registration: April 6, 2016.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00432-021-03847-5","type":"journal-article","created":{"date-parts":[[2022,2,19]],"date-time":"2022-02-19T07:02:34Z","timestamp":1645254154000},"page":"811-817","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Anti-CD20\u2013atezolizumab\u2013polatuzumab vedotin in relapsed\/refractory follicular and diffuse large B-cell lymphoma"],"prefix":"10.1007","volume":"149","clinical-trial-number":[{"clinical-trial-number":"nct02729896","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0135-1051","authenticated-orcid":false,"given":"Max S.","family":"Topp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herbert","family":"Eradat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Florsch\u00fctz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Hochhaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Wrobel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Walewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanda","family":"Knopinska-Posluszny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abraham S.","family":"Kanate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Lech-Maranda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uta","family":"Brunnberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surya","family":"Chitra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina G.","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gila","family":"Sellam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahesh","family":"Shivhare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izidore S.","family":"Lossos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,18]]},"reference":[{"key":"3847_CR1","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1200\/JCO.2017.77.6385","volume":"14","author":"JR Brahmer","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Thompson JA (2018) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline Summary. J Oncol Pract 14:247\u2013249. https:\/\/doi.org\/10.1200\/JCO.2017.77.6385","journal-title":"J Oncol Pract"},{"key":"3847_CR2","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1182\/blood-2016-05-718528","volume":"128","author":"BD Cheson","year":"2016","unstructured":"Cheson BD, Ansell S, Schwartz L et al (2016a) Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy. Blood 128:2489\u20132496. https:\/\/doi.org\/10.1182\/blood-2016-05-718528","journal-title":"Blood"},{"key":"3847_CR3","doi-asserted-by":"publisher","first-page":"766","DOI":"10.3109\/10428194.2015.1099647","volume":"57","author":"BD Cheson","year":"2016","unstructured":"Cheson BD, Brugger W, Damaj G et al (2016b) Optimal use of bendamustine in hematologic disorders: Treatment recommendations from an international consensus panel\u2014an update. Leuk Lymphoma 57:766\u2013782. https:\/\/doi.org\/10.3109\/10428194.2015.1099647","journal-title":"Leuk Lymphoma"},{"key":"3847_CR4","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.currproblcancer.2016.12.001","volume":"41","author":"LK Collins","year":"2017","unstructured":"Collins LK, Chapman MS, Carter JB, Samie FH (2017) Cutaneous adverse effects of the immune checkpoint inhibitors. Curr Probl Cancer 41:125\u2013128. https:\/\/doi.org\/10.1016\/j.currproblcancer.2016.12.001","journal-title":"Curr Probl Cancer"},{"key":"3847_CR5","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.cellimm.2014.05.006","volume":"290","author":"S Dai","year":"2014","unstructured":"Dai S, Jia R, Zhang X, Fang Q, Huang L (2014) The PD-1\/PD-Ls pathway and autoimmune diseases. Cell Immunol 290:72\u201379. https:\/\/doi.org\/10.1016\/j.cellimm.2014.05.006","journal-title":"Cell Immunol"},{"key":"3847_CR6","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/bjh.15232","volume":"182","author":"CL Freeman","year":"2018","unstructured":"Freeman CL, Sehn LH (2018) A tale of two antibodies: obinutuzumab versus rituximab. Br J Haematol 182:29\u201345. https:\/\/doi.org\/10.1111\/bjh.15232","journal-title":"Br J Haematol"},{"key":"3847_CR7","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3109\/02841860903150502","volume":"49","author":"G Gao","year":"2010","unstructured":"Gao G, Liang X, Jiang J et al (2010) A systematic review and meta-analysis of immunochemotherapy with rituximab for B-cell non-Hodgkin\u2019s lymphoma. Acta Oncol 49:3\u201312. https:\/\/doi.org\/10.3109\/02841860903150502","journal-title":"Acta Oncol"},{"key":"3847_CR8","doi-asserted-by":"publisher","first-page":"4023","DOI":"10.1158\/1078-0432.CCR-15-2872","volume":"22","author":"SM Goldinger","year":"2016","unstructured":"Goldinger SM, Stieger P, Meier B et al (2016) Cytotoxic cutaneous adverse drug reactions during anti-PD-1 therapy. Clin Cancer Res 22:4023\u20134029. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-2872","journal-title":"Clin Cancer Res"},{"key":"3847_CR9","volume-title":"Robbins and cotran pathologic basis of disease","author":"V Kumar","year":"2015","unstructured":"Kumar V, Abbas A, Aster J (2015) Robbins and cotran pathologic basis of disease, 9th edn. Elsevier, Philadelphia","edition":"9"},{"key":"3847_CR10","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1172\/JCI99036","volume":"128","author":"SM Liudahl","year":"2018","unstructured":"Liudahl SM, Coussens LM (2018) B cells as biomarkers: predicting immune checkpoint therapy adverse events. J Clin Invest 128:577\u2013579. https:\/\/doi.org\/10.1172\/JCI99036","journal-title":"J Clin Invest"},{"key":"3847_CR11","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","volume":"54","author":"JM Michot","year":"2016","unstructured":"Michot JM, Bigenwald C, Champiat S et al (2016) Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer 54:139\u2013148. https:\/\/doi.org\/10.1016\/j.ejca.2015.11.016","journal-title":"Eur J Cancer"},{"key":"3847_CR12","doi-asserted-by":"publisher","first-page":"e254","DOI":"10.1016\/S2352-3026(19)30026-2","volume":"6","author":"F Morschhauser","year":"2019","unstructured":"Morschhauser F, Flinn IW, Advani R et al (2019) Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS). Lancet Haematol 6:e254\u2013e265. https:\/\/doi.org\/10.1016\/S2352-3026(19)30026-2","journal-title":"Lancet Haematol"},{"key":"3847_CR13","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1002\/hon.2437_126","volume":"35","author":"ML Palomba","year":"2017","unstructured":"Palomba ML, Till B, Park SI et al (2017) A phase IB study evaluating the safety and clinical activity of atezolizumab combined with obinutuzumab in patients with relapsed or refractory non-Hodgkin lymphoma (NHL). Hematol Oncol 35:137\u2013138. https:\/\/doi.org\/10.1002\/hon.2437_126 (Abstract)","journal-title":"Hematol Oncol"},{"issue":"Suppl","key":"3847_CR14","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1182\/blood.V128.22.622.622","volume":"128","author":"T Phillips","year":"2016","unstructured":"Phillips T, Brunvand M, Chen A et al (2016) Polatuzumab vedotin combined with obinutuzumab for patients with relapsed or refractory non-Hodgkin lymphoma: preliminary safety and clinical activity of a phase Ib\/II study. Blood 128(Suppl):622. https:\/\/doi.org\/10.1182\/blood.V128.22.622.622 (Abstract)","journal-title":"Blood"},{"key":"3847_CR15","doi-asserted-by":"publisher","first-page":"378","DOI":"10.4103\/0366-6999.150111","volume":"128","author":"YR Ren","year":"2015","unstructured":"Ren YR, Jin YD, Zhang ZH, Li L, Wu P (2015) Rituximab treatment strategy for patients with diffuse large B-cell lymphoma after first-line therapy: a systematic review and meta-analysis. Chin Med J (Engl) 128:378\u2013383. https:\/\/doi.org\/10.4103\/0366-6999.150111","journal-title":"Chin Med J (engl)"},{"key":"3847_CR16","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/S1470-2045(16)30097-3","volume":"17","author":"LH Sehn","year":"2016","unstructured":"Sehn LH, Chua N, Mayer J et al (2016) Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial. Lancet Oncol 17:1081\u20131093. https:\/\/doi.org\/10.1016\/S1470-2045(16)30097-3","journal-title":"Lancet Oncol"},{"key":"3847_CR17","unstructured":"TECENTRIQ\u00ae (atezolizumab) injection, for intravenous use. Full prescribing information. Genentech, Inc., CA, USA. (2019). https:\/\/www.gene.com\/download\/pdf\/tecentriq_prescribing.pdf. Accessed 19 Mar 2021"},{"key":"3847_CR18","doi-asserted-by":"publisher","first-page":"e256","DOI":"10.3324\/haematol.2019.233189","volume":"105","author":"MS Topp","year":"2020","unstructured":"Topp MS, Duell J, Abajo Guijarro AM et al (2020) Treatment-refractory T-cell-mediated immune skin toxicities observed with obinutuzumab\/rituximab-atezo-pola in two patients with follicular lymphoma. Haematologica 105:e256-260. https:\/\/doi.org\/10.3324\/haematol.2019.233189","journal-title":"Haematologica"},{"key":"3847_CR19","unstructured":"US Food and Drug Administration (2019) FDA approves polatuzumab vedotin-piiq for diffuse large B-cell lymphoma. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-polatuzumab-vedotin-piiq-diffuse-large-b-cell-lymphoma. Accessed 19 Mar 2021"},{"key":"3847_CR20","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cellimm.2016.09.009","volume":"310","author":"MR Zamani","year":"2016","unstructured":"Zamani MR, Aslani S, Salmaninejad A, Javan MR, Rezaei N (2016) PD-1\/PD-L and autoimmunity: a growing relationship. Cell Immunol 310:27\u201341. https:\/\/doi.org\/10.1016\/j.cellimm.2016.09.009","journal-title":"Cell Immunol"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-021-03847-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-021-03847-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-021-03847-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,17]],"date-time":"2023-02-17T07:09:34Z","timestamp":1676617774000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-021-03847-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,18]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["3847"],"URL":"https:\/\/doi.org\/10.1007\/s00432-021-03847-5","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,18]]},"assertion":[{"value":"31 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"H.E. reported: research funding, honoraria, or consulting fees from AbbVie, Genentech, Inc., Kite, Gilead Sciences, Takeda, Acerta, AstraZeneca, BeiGene and Juno. M.T. reported: research grants from Amgen, Gilead Sciences, Macrogenics, F. Hoffmann-La Roche Ltd, and Regeneron; consulting fees from Amgen and F. Hoffmann-La Roche Ltd; and advisory board membership for Amgen and Regeneron. T.W. reported: research grants and advisory board membership for F. Hoffmann-La Roche Ltd, Amgen, and Novartis; lecture fees from F. Hoffmann-La Roche Ltd, Novartis, and Celgene; and advisory board membership for Celgene. I.S.L. reported: advisory board membership for Seattle Genetics and Janssen Scientific. J.W. reported: advisory board membership for F. Hoffmann-La Roche Ltd, Celgene, Takeda, Janssen-Cilag, Servier, Amgen, BMS, Incyte, and AbbVie; research funding from F. Hoffmann-La Roche Ltd, GSK\/Novartis, Takeda, Janssen-Cilag, and AbbVie; lecture honoraria from F. Hoffmann-La Roche Ltd, Celgene, Takeda, Janssen-Cilag, and Servier; and conference travel support from Roche. U.B. reported: advisory board membership for F. Hoffmann-La Roche Ltd, Gilead Sciences, Janssen, MSD, and Hexal; and travel grants from Janssen, Amgen, F. Hoffmann-La Roche Ltd, and Gilead Sciences. A.H. reported: research support by F. Hoffmann-La Roche Ltd, Novartis, BMS, Pfizer, and Incyte. E.L.M. reported: advisory board membership for F. Hoffmann-La Roche Ltd, Gilead Sciences, Takeda, Janssen-Cilag, Amgen, Novartis, AbbVie, and Celgene; lecture honoraria from F. Hoffmann-La Roche Ltd, Janssen-Cilag, Amgen; and conference travel support from F. Hoffmann-La Roche Ltd, Janssen-Cilag, and Amgen. W.K-P. declared no disclosures to report. A.S.K reports that West Virginia University, WV, USA directly received research funding outside the submitted work. T.N., S.C., M.S. and G.S. declared employment at F. Hoffmann-La Roche Ltd\/Genentech, Inc. T.N. declared stock ownership at F. Hoffmann-La Roche Ltd\/Genentech, Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Qualified researchers may request access to individual patient level data through the clinical study data request platform (). Further details on Roche's criteria for eligible studies are available here: (). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here: ().","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}}]}}